Navigation Links
Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells
Date:12/10/2008

k status and orphan-drug designation for the treatment of malignant mesothelioma by the FDA. Additionally, ONCONASE has been granted orphan-drug designation in the European Union and Australia.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. For more information, visit www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainty whether the clinical trial results will allow the company to complete submission of a New Drug Application and if a New Drug Application submission is completed, uncertainty whether FDA will file or approve such application, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials or differences of opinion in interpreting the results of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's perio
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
2. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
3. New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
4. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
5. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
6. ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
7. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
8. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
9. Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... Pharnext SAS today announced that data related to its ... Type 1A (CMT1A), is being presented in four posters and ... Biennial Meeting at the Quebec Congress Center in ... 2015. At Poster Viewing Session 4, four posters ... EDT: Poster 23: "A Meta-Analysis Of Randomized ...
(Date:6/29/2015)... June 29, 2015  MiMedx Group, Inc. (NASDAQ: ... amniotic tissue and patent-protected processes to develop and market ... Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of ... "Pete" Petit, has been awarded the Lifetime Achievement Award ... Program. The Entrepreneur Of The Year ...
(Date:6/29/2015)... --  For the seventh year running, Across Health conducted a ... maturity called the Multichannel Maturometer . The research ... fast enough. While it,s true that technology is indeed ... customers are increasingly "digital natives", pharma still lags behind ... Logo ...
(Date:6/26/2015)... ... June 26, 2015 , ... ... Agriculture (USDA), Grain Inspection, Packers and Stockyards Administration (GIPSA) awarded a five year ... in feed and grains utilizing Charm’s ROSA DONQ-FAST5 Test. This 5 minute quantitative ...
Breaking Biology Technology:Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting 2EY Entrepreneur Of The Year Program Recognizes Pete Petit, The Chairman & CEO of MiMedx 2Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4USDA-GIPSA (FGIS) Awards 5 Year Contract for Vomitoxin Tests to Charm Sciences 2
... www.tedmed.com , the world,s leading multi-disciplinary conference on the future ... of the conference will take place in Washington, DC at ... April 11-13, 2012. From 2009 to 2011, San ... and technology developers. The move to the Nation,s Capital and ...
... -- Andrew Barron, Rice University,s Charles W. Duncan, Jr. ... science, is the winner of the prestigious 2011 World ... the World Technology Summit and Awards gala at the ... the application of nanotechnology to fundamental problems in energy ...
... VetNostic Laboratories® offers state-of-the-art genetic testing services for ... are able to accurately and specifically determine whether ... reliable identification of these "carriers" ensures healthy litters ... VetNostic Laboratories® is pleased to introduce two new ...
Cached Biology Technology:TEDMED Announces Move to Washington, DC; the John F. Kennedy Center for Performing Arts Will Host TEDMED 2012 Conference 2TEDMED Announces Move to Washington, DC; the John F. Kennedy Center for Performing Arts Will Host TEDMED 2012 Conference 3TEDMED Announces Move to Washington, DC; the John F. Kennedy Center for Performing Arts Will Host TEDMED 2012 Conference 4TEDMED Announces Move to Washington, DC; the John F. Kennedy Center for Performing Arts Will Host TEDMED 2012 Conference 5Rice's Barron wins World Technology Award for Materials 2VetNostic Laboratories® Announces New Testing for Dog Breeds 2VetNostic Laboratories® Announces New Testing for Dog Breeds 3
(Date:6/16/2015)... , June 16, 2015 /CNW Telbec/ - ... partnership centralized around the incorporation of handyem,s HPC-150 ... diagnostic laboratory, the Mo-POD™. This unprecedented model of ... International Conference at the Pennsylvania ... from June 15 th to 18 th ...
(Date:6/16/2015)... Fingerprint Cards (FPC) raises the revenue guidance for ... at least 340 MSEK to that it will amount to ... growth and orders received the revenue guidance for 2015 is ... will exceed 1,500 MSEK to an updated guidance that revenue ... Due to receipt of orders of touch fingerprint sensors with ...
(Date:6/15/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... market, announces that its leading payment security technology, the Wocket® ... @ NYC June 18th. Digital Experience! @ NYC ... technology to over 300 of the top media covering the ... in New York City from 6:00 ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3
... cells become after being exposed to a specialized electrical ... cancerous or a stage of cancer already invading other ... the electrical process and found cells that expanded the ... disease has spread beyond its point of origin. The ...
... power to constrict blood vessels and help patients manage ... more about how endothelin functions naturally and in disease ... Despite strong laboratory evidence that blocking endothelin-1 receptors would ... health problems, the drugs failed patients, says Dr. Adviye ...
... Within the last few years the number of ... increased considerably. A worthwhile effort as, after all, it concerns ... of transport checks are offered by terahertz radiation. Before this ... to be measured quantitatively, so that damage to health caused ...
Cached Biology News:Expanding cell girth indicates seriousness of breast cancer 2Better understanding of blood vessel constrictor needed to harness its power for patients 2Checking people at airports -- with terahertz radiation 2
... containing an overproducing clone of M-MLV Reverse ... the polymerization of DNA using template DNA, ... large mRNAs, >10 kb, may be synthesized. ... RNase H activity than AMV Reverse Transcriptase ...
... catalyzes the template-directed polymerization of nucleotides into ... Polymerase I possesses a 3?5 exonuclease activity ... rate during DNA replication, and also contains ... enzyme to replace nucleotides in the growing ...
Request Info...
... yeast/leuconostoc overproducer ATP: D-hexose 6- ... One unit of HK will ... in 1 min at 25C ... of G6P-DH will oxidize 1 ...
Biology Products: